Association of Chemotherapy for Solid Tumors With Development of Therapy-Related Myelodysplastic Syndrome or Acute Myeloid Leukemia in the Modern Era | Zendy

Lindsay M. Morton | Zendy; Graça M. Dores | Zendy; Sara J. Schonfeld | Zendy; Martha S. Linet | Zendy; Byron Sigel | Zendy; Clara Lam | Zendy; Margaret A. Tucker | Zendy; Rochelle E. Curtis | Zendy

Open Access

Association of Chemotherapy for Solid Tumors With Development of Therapy-Related Myelodysplastic Syndrome or Acute Myeloid Leukemia in the Modern Era

Author(s) -

Lindsay M. Morton,

Graça M. Dores,

Sara J. Schonfeld,

Martha S. Linet,

Byron Sigel,

Clara Lam,

Margaret A. Tucker,

Rochelle E. Curtis

Publication year - 2018

Publication title -

jama oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 8.846

H-Index - 99

eISSN - 2374-2445

pISSN - 2374-2437

DOI - 10.1001/jamaoncol.2018.5625

Subject(s) - medicine , chemotherapy , myeloid leukemia , oncology , cancer , myelodysplastic syndromes , population , surveillance, epidemiology, and end results , epidemiology , cancer registry , bone marrow , environmental health

Therapy-related myelodysplastic syndrome or acute myeloid leukemia (tMDS/AML) is a rare, usually fatal complication of chemotherapy, including certain alkylating agents, topoisomerase II inhibitors, and platinum compounds. With the introduction of new chemotherapeutic agents, expanded indications for established agents, and increased neoadjuvant and adjuvant chemotherapy, tMDS/AML risks in the modern age are poorly understood.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research